8-K
filed March 31, 2026, 7:59 PM ET
ticker APLS
CIK 0001492422
M&A
confidence high
sentiment positive
materiality 0.90
Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share
Apellis Pharmaceuticals, Inc.
- Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).
- CVRs entitle holders to up to $4.00/share based on SYFOVRE net sales milestones ($1.5B or $2B).
- Tender offer to commence for all shares; no stockholder vote required; minimum condition >50% tendered.
- Support stockholders owning ~14% of shares agree to tender; termination fee $205M under certain conditions.
- Apellis board unanimously recommends; deal expected to close by Sept 30, 2026.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-134916
- form_type
- 8-K
- ticker
- APLS
- cik
- 0001492422
- company_name
- Apellis Pharmaceuticals, Inc.
- filed_at
- 2026-03-31T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.213320+00:00
- generated_at
- 2026-05-15T08:09:01.101931+00:00
- sec_items
- ["1.01", "5.02", "8.01", "9.01"]
- event_type
- m_and_a
- sentiment
- positive
- materiality_score
- 0.9
- calibrated_materiality_score
- 0.9
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-134916
- json_url
- https://secwatch.observer/filing/0001193125-26-134916.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-134916.md
- text_url
- https://secwatch.observer/filing/0001193125-26-134916.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/0001193125-26-134916-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1492422/000119312526134916/d132653d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
EWCZ
European Wax Center completes take-private by General Atlantic at $5.80/share; stock delisted
European Wax Center, Inc.
May 8, 2026, 7:59 PM ET
m_and_a
Items 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.02, 5.03, 5.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 5.02, 8.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
As previously disclosed, European Wax Center, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger, dated as of February 9, 2026 (the “ Merger Agreement ”), by and among Glow Midco, LLC, a Delaware limited liability company (“ Parent ”), Glow Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub Inc. ”), Glow Merger Sub 2, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (“ Merger Sub LLC ,” and together with Merger Sub Inc., the “ Merger Subs ”) and EWC Ventures, LLC, a Delaware limited liability company (“ Opco ”), pursuant to which (i) Merger Sub Inc. merged with and into the Company (the “ Corporate Merger ”), with the Company surviving the Corporate Merger as the surviving corporation (the “ Surviving Corporation ”) and a wholly owned subsidiary of Parent and (ii) Merger Sub LLC merged with and into Opco, with Opco surviving as the surviving limited liability company
Filing page
SEC filing
NCSM
Weatherford to acquire NCS Multistage for 0.463 shares per NCS share; expected close H2 2026
NCS Multistage Holdings, Inc.
June 1, 2026, 8:43 PM ET
m_and_a
Items 1.01, 5.07, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
On May 31, 2026, NCS Multistage Holdings, Inc., a Delaware corporation (“ NCS ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among NCS, Weatherford International plc, an Irish public limited company (“ Weatherford ”), and Trinity Bell Sub, Inc., a Delaware corporation and wholly owned subsidiary of Weatherford (“ Merger Sub ”), pursuant to which, upon the terms and subject to the conditions set forth therein, Merger Sub will merge with and into NCS (the “ Merger ”), with NCS surviving the Merger as a wholly owned subsidiary of Weatherford.
Filing page
SEC filing
Enviri II Corp
New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA
Enviri II Corp
June 1, 2026, 5:18 PM ET
m_and_a
Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 5.02, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
On June 1, 2026, New Enviri entered into a transition services agreement (the “Transition Services Agreement”) with CLEH pursuant to which New Enviri will provide certain services to CLEH on an interim, transitional basis.
Filing page
SEC filing
EEX
Apollo Funds acquire Emerald (EEX) for $5.03/sh (42% premium); combine with Questex
Emerald Holding, Inc.
May 11, 2026, 7:59 PM ET
m_and_a
Items 1.01, 5.07, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
On May 9, 2026, Emerald Holding, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Emma Buyer, LLC, a Delaware limited liability company (“ Parent ”), and Emma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”).
Filing page
SEC filing
KLXE
KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity
KLX Energy Services Holdings, Inc.
June 2, 2026, 5:14 PM ET
m_and_a
Items 1.01, 2.01, 3.02, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
Purchase and Sale Agreement On June 2, 2026 (the “Closing Date”), KLX Energy Services Holdings, Inc., a Delaware corporation (the “Company”), completed the acquisition (the “Acquisition”) of certain assets owned by Wolf Pack Rentals, LLC, a Texas limited liability company (“Wolf Pack” or the “Seller”), pursuant to that certain asset purchase agreement, dated June 2, 2026 , by and among Wolf Pack, KLX Energy Services LLC, a Delaware limited liability company and indirect wholly owned subsidiary of the Company (the “Buyer”), the Company and, solely for purposes of Section 8.05 thereto, Stevie Cooper and Stewart Cooper (the “Purchase Agreement”).
Filing page
SEC filing
XRN
Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred
Chiron Real Estate Inc.
June 2, 2026, 4:30 PM ET
m_and_a
Items 1.01, 2.01, 2.03, 3.02, 3.03, 5.03, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
Item 1.01 Entry into a Material Definitive Agreement Seventh Amendment to the Agreement of Limited Partnership of Chiron Real Estate LP On May 28, 2026, Chiron Real Estate Inc. (the “ Company ”), as the sole member of the general partner of Chiron Real Estate LP (the “ Operating Partnership ”), entered into an amendment to the agreement of limited partnership of the Operating Partnership (the “ OP Amendment ”).
Filing page
SEC filing
WLY
Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one
JOHN WILEY & SONS, INC.
June 2, 2026, 8:30 AM ET
m_and_a
Items 1.01, 2.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
entered into an Equity Purchase Agreement (the "Purchase Agreement") with CIG Emerald Midco LLC, a Delaware limited liability company (the "Seller"), and CIG Emerald Holding LLC, a Delaware limited liability company ("Emerald Holding"), pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the "Transaction") in exchange for GBP £337.5 million (approximately $452 million)
Filing page
SEC filing
TVTX
Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones
Travere Therapeutics, Inc.
June 2, 2026, 7:05 AM ET
m_and_a
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Parent”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”).
Comparable filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.